

PRESENTED BY



Australian Prostate Cancer Research

#### **31 AUGUST - 2 SEPTEMBER 2014** MELBOURNE CONVENTION AND EXHIBITION CENTRE Melbourne, Australia

CLINICAL UROLOGY | TRANSLATIONAL SCIENCE | NURSING & ALLIED HEALTH

# TOGETHER IN DISCOVERY AND CARE COME TOGETHER

### **Conference** Program

www.prostatecancerconference.org.au



Follow us on twitter #apcc14 @AustProstate



# Overall survival<sup>1-5\*</sup>

\*Adjuvant goserelin and radiotherapy (RT) together significantly improved overall survival compared to RT alone in patients with locally advanced prostate cancer.

**PBS Information:** Zoladex 10.8 mg. Authority Required (STREAMLINED). Locally advanced (equivalent to stage C) or metastatic (equivalent to stage D) carcinoma of the prostate.

Before prescribing, please review full Product Information available on request from AstraZeneca on 1800 805 342 or www.astrazeneca.com.au/Pl

Zoladex<sup>®</sup> 10.8 mg Implant (goserelin acetate) Indications: Palliative treatment of metastatic (M+) or locally advanced prostate cancer; adjuvant and neoadjuvant therapy in combination with radiotherapy for the management of locally advanced prostate cancer, in men suitable for hormonal manipulation. Dosage: One implant (10.8 mg) injected subcutaneously into anterior abdominal wall every 3 months. Contraindications: Hypersensitivity to LHRH, LHRH agonist analogues or any components of ZOLADEX. Precautions: Patients with metastatic cancer at risk of developing ureteric obstruction or spinal cord compression; males with diabetes (monitor blood glucose); not indicated for use in females; not indicated for use in children; bone pain; serum testosterone concentrations may rise if implant omitted or delayed; loss of bone mineral density; *monitor blood glucose and or glycosylated haemoglobin (HbA1c) periodically in patients receiving a GnRH agonist should be monitored for symptoms and signs suggestive of development of cardiovascular disease and manage daccording to current clinical practice.<sup>\*</sup> Interactions: None known. Adverse reactions: Very common (≥10%); decreased libido, hot flush, abnormal blood pressure, hyperhidrosis, erectile dysfunction, gynaecomastia, breast tenderness, paraesthesia, decreased bone mineral density; <i>Common (≥1% to <10%)*; impaired glucose tolerance, spinal cord compression, incontinence/urinary frequency (post-radiotherapy), rash, bone pain, arthraligia, injection site reaction, cardiac failure, myocardial infarction, increased weight, *mood swings*\*; For less common adverse reactions to 10 Reproved Product Information Date of GA approval 11 November 2010. Date of most recent amendment: 4 September 2012. References: 1. Zoladex 10.8 mg Approved Product Information. Date of GA approval 11 November 2010. Date of most recent amendment: 4 September 2012. 2. Bola M et al. *Lancet Oncol 2010*, 11(11): 1066–73. 3. Bolla M et al. *N Engl J Med* 1997; 337: 295–300, 4. Bolla M *et al. Lancet* 2002;

\*Please note changes in Product Information.



### Sponsors and Partners

We thank our Sponsors and Partners for their support.



### Contents

Welcome	4
Host and Committees	6
International Speakers	8-9
National Speakers	10
<b>Program</b> Sunday 31st August Monday 1st September Tuesday 2nd September Janssen Satellite Symposium	11-12 12-15 16-17 19
<b>Posters</b> Clinical Urology Nursing & Allied Health Translational Science	20-21 22-23 24
Clinical Urology Meeting	25
Nursing & Allied Health	26-27
Translational Science Program	28
Masterclasses	29-31
Social Program	32
Registration Information	33
Presentation Information	34
Melbourne	34-35
General Information	36
Exhibition Information	37-38
Exhibitor Profiles	39-45

### Welcome!

Welcome to the 15th Asia-Pacific Prostate Cancer Conference. We are proud to again bring the world's experts together and celebrate 15 years of industry education this year.

2014 brings with it a number of new educational opportunities for attendees, including the MRI Masterclass, which sold out swiftly. As always, the Conference will empower our health care industry to implement improved patient care practices and provide up to date information for patients to make informed choices.

Men's health will feature more broadly this year, with opinion leaders addressing the lag in specialist services for men. The program also includes specialised meetings for all practitioners involved in prostate cancer care delivery including: Urologists, Radiologists Radiation Oncologists, Medical Oncologists, Researchers, Nurses, General Practitioners, Psycho-Oncologists, Physiotherapists and more.

We look forward to welcoming you in coming together as an industry for this international event in Melbourne. Thank you for participating and we hope you find the 15th Asia-Pacific Prostate Cancer Conference informative and inspiring.



Prof Tony Costello President, 15th Asia-Pacific Prostate Cancer Conference Executive Director, Australian Prostate Cancer Research





### Collaboration, support and innovation in prostate cancer.

www.tolmar.com.au

Tolmar Australia Pty Ltd. ABN 53 162 640 708. Level 2/20 Bridge St, Pymble, NSW 2073. Ph: 1800 TOLMAR(865 627). TOL140267. June 2014. AM5341.



Australian Prostate Cancer **Research** 



Australian Prostate Cancer Research is a national research organisation that partners with leading institutions to develop, fund and deliver national research programs. We are committed and driven to discover the cause of prostate cancer, improve patient outcomes and educate people on all aspects of diagnosis, treatment and patient care, thereby empowering men and their families. www.prostatecancerresearch.org.au

Australian Prostate Cancer Research would like to thank the following individuals for their involvement in the 15th Asia-Pacific Prostate Cancer Conference.

#### Asia-Pacific Prostate Cancer Conference – Founder & Convenor

**Prof Anthony Costello** 

Executive Director, Australian Prostate Cancer Research, Director of Urology, Royal Melbourne Hospital

#### Local Organising Committee

#### Program Secretary Dr Phil Dundee

Royal Melbourne Hospital, Western General Hospital, Epworth Prostate Centre

#### Clinical Urology Stream Convenor A/Prof Declan Murphy

Urologist and Director of Robotic Surgery, Peter MacCallum Cancer Centre, Epworth Prostate Centre

#### Translational Science Convenors Dr David Sandall

Chief Operating Officer, Epworth Prostate Centre,

#### **Prof John Mills**

Director of Research and Development, TissuPath Specialist Pathology

### Nursing & Allied Health Stream Convenors

#### Ms Helen Crowe

Prostate Cancer Nurse Practitioner, Research Nurse, Epworth Prostate Centre

#### **Dr Addie Wootten**

Clinical Psychologist, Department of Urology, The Royal Melbourne Hospital. Director of Clinical & Allied Health Research, Epworth Prostate Centre, eHealth Research Manager; Australian Prostate Cancer Research

#### **Dr Jane Crowe**

Private General Practitioner & Prostate Cancer Physician, Epworth Prostate Centre

#### **Mr James Garland**

CEO, Australian Prostate Cancer Research

#### **Mrs Sally Marasco**

Business Development Manager, Australian Prostate Cancer Research, Conference Manager

We are also grateful for the support of the program stream sub committee members whom are acknowledged on the program stream page.

## MENS CLINC 14-20 BLACKWOOD ST NORTH MELBOURNE

Before the end of 2014, Australian Prostate Cancer Research will open to the general public Australia's first dedicated facility for men with prostate cancer and related health issues.

Located within the Parkville medical and research precinct, the facility boasts its own street foyer access, patient undercover off-street parking and a 'non clinic' lounge style presentation upon entry to the centre.

The research facilities will host the unique prostate biorepository and the downstream analysis capabilities of the Clinic.

Complete with consultation suites, a pathology service, procedure rooms, gymnasium, allied health services, counselling, education and robotic surgery training facility - the Clinic will provide a multi-disciplinary and integrated service approach to cater for all patient needs. Australia is about to experience a revolution the delivery of healthcare for men!

> For more information please visit the APCR stand or website: prostatecancerresearch.org.au



Australian Prostate Cancer Research



### International Speakers



#### Dr Mitchell Benson

(USA) Urology faculty at Columbia University and former Chair of the Department of Urology



#### Prof Jelle Barentsz

(Netherlands) Radbound University Medical Centre Department of Radiology



#### Dr Peter Carroll

(USA) Faculty in the Department of Urology at UCSF

#### Mr Paul Cathcart

(UK) Senior Lecturer in Genito-urinary Oncology Consultant Urological Surgeon Prostate Cancer Lead – St Bartholomew's Hospital



#### Dr Matthew Cooperberg

#### (USA)

London

A/Prof, Depts of Urology & Epidemiology & Biostatics, University of California, San Francisco, Helen Diller Family Comprehensive Cancer Centre



#### Dr Juanita Crook

(Canada) Kelowna General Hospital

#### Dr John Davis

(Netherlands) Associate Professor of Urology and Director of the prostate cancer surgery program at MD Anderson Cancer Center



#### Mr Markus Graefen

(USA) Martini-Clinic, Prostate Cancer Center at the University of Hamburg







### Prof Larry Goldenberg

(Canada) Professor and Head, Department of Urologic Sciences, University of British Columbia

#### Prof Roger Kirby

(UK) Consultant Urologist, Director of The Prostate Centre

#### Mr Thomas Lynch

(Ireland) Consultant Urological Surgeon at St. James's Hospital and Trinity College, Dublin

### International Speakers continued



#### Dr Christian Nelson

(USA)

Psychological liaison to Memorial Sloan Kettering's genitourinary and sexual medicine services



#### Dr Matthew Smith

(USA) Director of the Genitourinary Malignancies Program at Massachusetts General Hospital and Professor of Medicine at Harvard Medical School



#### Prof Bertrand Tombal

(Belgium) Chairman of the Division of Urology, Cliniques Universitaires Saint-Luc, Brussels



(Netherlands) Department of Urology, Netherlands Cancer Institute

# Your choice can make a difference





#### Ferring Pharmaceuticals Pty Ltd.

Suite 2, Level 1, Building 1, 20 Bridge Street, Pymble, NSW, 2073. Ph: +61 2 9497 2300 Fax: +61 2 9497 2399 Toll free: 1800 337 746 Email: enquiries@ferring.com FN/634/2014/AU Date prepared April 2014.



### National Speakers

#### Dr Arun Azad

British Columbia Cancer Agency

Dr Pat Bowden Director of Epworth Radiation Oncology

#### Dr Prue Cormie

Edith Cowan University, Health and Wellness Institute

#### Prof Mark Frydenberg

Chairman, Department of Urology, Monash Medical Centre; Chairman, Institute of Specialty Surgery, Epworth Healthcare

#### Prof Daniel Galveo

Edith Cowan University, Health and Wellness Institute

#### Mr Jeremy Grummet Australian Urology Associates

A/Prof Chris Hovens The University of Melbourne, Epworth Prostate Centre

#### Dr Joe Ischia Austin Health

#### A/Prof Nathan Lawrentschuk

Department of Surgery, Austin Hospital; Peter MacCallum Cancer Centre

#### **Prof Robert Newton**

Edith Cowan University, Health and Wellness Institute



### Dr Patricia Neumann The Pelvic Floor Clinic Dr Max Rutherford The Royal Melbourne Hospital A/Prof Penelope Schofield Peter MacCallum Cancer Centre Dr Shomik Sengupta The Austin Hospital Dr Ryan Stafford The University of Queensland Ms Kay Talbot Australian Urology Associates Dr Ben Tran The Royal Melbourne Hospital Mr Mark Trevaskis

Edith Cowan University, Health and Wellness Institute

#### A/Prof Scott Williams Peter MacCallum Cancer Centre

Ms Sarah Woollet Independent Researcher

Dr Addie Wootten Australian Prostate Cancer Research

### Sunday 31st August 2014

0800	4th da Vinci Prostate Room 219	ectomy Masterclass		Nursing & Allied Health Continence
	See page 29 for full program details			Plenary 3
		rogram dotano		Chairs: Shan Morrison and Adam Landau
				0800 Welcome   Addie Wootten and Helen Crowe
				0805 Qualitative experiences of patients with incontinence   Sarah Woollet
				0830 Dynamics of the male pelvic floor   Ryan Stafford
				0900 Teaching pelvic floor exercises to men before prostate surgery – what is best practice?   <i>Trish Neumann</i>
				0930 The impact of incontinence on sexual intimacy   Panel discussion with Roger Kirby
1000- 1030	MORNING TEA			
1030- 1230	4th da Vinci	LDR	Prostate MRI	Nursing & Allied Health
1230	Prostatectomy Masterclass	Brachytherapy Masterclass	Imaging & Biopsy Masterclass	Active Surveillance
	Room 219	Room 218	Room 220	Plenary 3
	See page 29 for full	See page 31 for full	See page 30 for full	Chairs: Kay Talbot and Paul Cathcart
	program details	program details	program details	1030 Setting the scene, Active Surveillance versus Watchful Waiting and an overview of the current management protocols for Active Surveillance   Mark Frydenberg
				1100 An overview of biopsy techniques and implications for the patient: Transperineal versus TRUS   Jeremy Grummet
				1130 The personal and psychosocial experiences of Active Surveillance   <i>Penelope Schofield</i>
				1200 Active Surveillance for Prostate Cancer – Potential Application of Exercise Medicine   Daniel Galveo
1230- 1330	LUNCH			
	4th da Vinci	LDR	Prostate MRI	Nursing & Allied Health
	Prostatectomy	Brachytherapy	Imaging & Biopsy	Hormone Therapy
	Masterclass	Masterclass	Masterclass	Plenary 3
	Room 219	Room 218	Room 220	Chairs: Addie Wootten and Robert Newton
	See page 29 for full program details	See page 31 for full program details	See page 30 for full program details	1330 Androgen Deprivation Therapy, Setting the scene: A brief overview   <i>Helen Crowe and Kay Talbot</i>
				1345 The physiological impact of Androgen Deprivation Therapy: Managing the side effects   <i>Jane Crowe</i>
				1410 The cognitive impact of hormone therapy   Christian Nelson
				1435 Improving mental wellbeing through exercise: a support group tailored for men with prostate cancer   <i>Prue Cormie</i>
	🛑 Clinical Urology 🛛 🔵 Ti	ranslational Science 🛛 🔴	Nursing & Allied Health	

### Sunday 31st August 2014

1500- AFTERNOON TEA

1530				
1530-	4th da Vinci Prostatectomy Masterclass Room 219 See page 29 for full program details	LDR Brachytherapy Masterclass Room 218 See page 31 for full program details	Prostate MRI Imaging & Biopsy Masterclass Room 220 See page 30 for full program details	Nursing & Allied Health         Advanced prostate cancer         Plenary 3         Chairs: Helen Crowe and Phil Dundee         1530 Reflections upon the provision of psychological support to men with Advanced Prostate Cancer   Max Rutherford         1550 New radiation therapy techniques for advanced prostate cancer   Pat Bowden         1610 New systemic treatments and agents for advanced prostate cancer   Ben Tran         1630 Panel discussion – the challenges of managing and supporting the complex advanced prostate cancer patient   Panel         1650 Discussion of resources available and how to access them         1655 Meeting close Addie Wootten & Helen Crowe
1700-	Poster and Welcome	Reception		

1900 Exhibition Area

### Monday 1st September 2014

0745-	Combined Multidisciplinary Plenary
0800	Plenary 3
	Chair: Tony Costello, Roger Kirby, Larry Goldenberg
	0745 Conference Opening & Welcome   Prof Tony Costello
	0800 Ministerial Address   Hon. Peter Dutton MP
	0815 Men's Health: The Final Piece of the Puzzle of Family Health   Larry Goldenberg
	0835 The trouble with men   Roger Kirby
	0840 Life without PSA testing – future predictions if the USPSTF had their way   Matthew Cooperberg
	0855 Characterisation of a high volume center for radical prostatectomy – perspectives beyond surgical expertise   Markus Graefen
	0910 State-of-the-Art mp-MRI: clinical role and PI-RADS reporting   Jelle Barentsz
	0925 The timing of androgen deprivation therapy – new perspectives in 2014   Bertrand Tombal
	0940 Optimal timing and sequencing of new androgen pathway inhibitors in castration-resistant prostate cancer   <i>Matthew Smith</i>
	0955 Questions
	0958 Prostate Cancer World Congress 2015 Announcement
1000- 1030	MORNING TEA

### Monday 1st September 2014

#### 1030

#### Plenary 3 Chair: Declan Murphy, Joseph Bucci

Oligometastatic disease

1030 Introduction | *Declan Murphy* 1035 The molecular imaging of oligometastatic disease | *Scott Williams* 

1050 Nodal Imaging revisited | Jelle Barentsz

1105 The role of radical prostatecomy in metastasized prostate cancer | *Markus Graefen* 

1120 Stereotactic radiotherapy for oligometastatic disease | Pat Bowden 1135 The choice of systemic therapies in low-volume metastatic disease | Ben Tran

1150 2nd Patrick C Walsh Lecture – Introduction | *Tony Costello* 

1200 2nd Patrick C Walsh Lecture: Refined prostate cancer risk assessment leads to refined treatment | Peter Carroll

#### Therapies Room 218

#### Chair: Prof Colleen Nelson

1030 Repositioning "Old" Drugs for New Causes: Identifying New Treatments for Metastatic Prostate Cancer | *Esha Shah* 

1045 BDX1: A natural small molecule activator of the amino acid stress response pathway in prostate cancer cells | *Michelle Liberio* 

1100 The Ascidian natural product EB activates DNA damage response pathways through inhibition of topoisomerase II in LNCaP cells | *Michelle Liberio* 

1115 Co-targeting H2 relaxin and androgen signalling in prostate cancer | *Gregor Tevz* 

1130 Mechanism of action studies in prostate cancer cells on new compounds isolated from an Australian endemic rainforest tree | *Claire Levrier* 

1145 Targeting neuropilin-1 to inhibit prostate cancer metastasis and therapy resistance | *Brett Hollier* 

#### 1205 Circulating microRNAs

associated with docetaxel chemotherapy outcome of prostate cancer | *Hui-Ming Lin* 

### Current Nursing and Allied Health Research Trends

#### Room 220

Chairs: Robert Newton and Christian Nelson

1030 Effects of a clinician's referral and physical activity program for men who have completed treatment for prostate cancer: A multicentre cluster randomized controlled trial [ENGAGE] | Patricia Livingston

1040 The efficacy of a clinician referred exercise training program on markers of cardiometabolic risk for prostate cancer survivors | Patrick Owen

1050 Preliminary results of My Road Ahead: An online psychological intervention for men with prostate cancer | Addie Wootten

1100 Engaging Men with Prostate Cancer: The development of a tumour specific Living with Cancer Education Program | *David Gray* 

1110 Self-esteem, body image, sexual and urinary function of gay and straight prostate cancer survivors: Is there really a difference? | *Christopher Thomas* 

1120 Reduction of fatigue in men on ADT for prostate cancer: effect of varying exercise modes | *Dennis Taaffe* 

1130 Are current definitions of depression inadequate for prostate cancer patients? | *Vicki Bitsika* 

1140 Pelvic Floor muscle contraction with verbal instruction- do men get it? | Patricia Neumann

1150 Psychological Distress and Advanced Prostate Cancer | Leah Zajdlewicz

1200 The efficacy of a clinician referred supervised exercise training program on fitness, body composition and physiological outcomes for prostate cancer survivors | *Steve Fraser* 

1210 Maximal exercise testing of men with prostate cancer being treated with ADT | *Bradley Wall* 

1220 Discussion and presentation of Best Oral Paper prize

### Monday 1st September 2014

1330- 1500       Patterns of Care, Risk Stratification and Active Surveillance       Metastasis and Progression Room 218         Chair: Nathan Lawrentschuk, Mark Frydenberg       Chair: Prof Pamela Russell         1330 Patterns of care for men with a prostate cancer diagnosis in Victoria Jeremy Millar       1330 Evading immune surveillance as a mechanism of prostate cancer metastasis to bone   Nikola Baschuk         1345 How we set up a National Prostate Cancer Audit – the English experience   Paul Cathcart       1345 Increased expression of the ETS1 transcription factor promotes epithelial-to-mesenchymal transition (EMT) in prostate cancer cells   Marc Thomas         1400 Point-counterpoint: we must do transperineal prostate biopsy   Jeremy Grummet       1400 Tie-2 regulates stemness and metastasis of prostate cancer cells   Patrick Ling         1410 Point-counterpoint: TRUS prostate biopsy is fine   Shomik Sengupta       1415 YB-1, a driver of prostate cancer progression   Anja Rockstroh         1420 Active surveillance – has the pendulum swung too far?   Nathan Lawrentschuk       1435 MicroRNA-194 promotes migration and invasion of prostate cancer cells by regulating epithelial- mesenchymal transition   Rajdeep Das         1440 Active surveillance for low risk prostate cancer - who, how and for how long   Peter Carroll       Pater Carroll	1230- 1330	LUNCH	
1455 Questions & Answers   Panel		and Active Surveillance Plenary 3 Chair: Nathan Lawrentschuk, Mark Frydenberg 1330 Patterns of care for men with a prostate cancer diagnosis in Victoria   <i>Jeremy Millar</i> 1345 How we set up a National Prostate Cancer Audit – the English experience   <i>Paul Cathcart</i> 1400 Point-counterpoint: we must do transperineal prostate biopsy   <i>Jeremy Grummet</i> 1410 Point-counterpoint: TRUS prostate biopsy is fine   <i>Shomik Sengupta</i> 1420 Active surveillance – has the pendulum swung too far?   <i>Nathan Lawrentschuk</i> 1425 Is active surveillance for low risk prostate cancer really safe?   <i>Mitchell Benson</i> 1440 Active surveillance for early- stage prostate cancer – who, how and for how long   <i>Peter Carroll</i>	Room 218         Chair: Prof Pamela Russell         1330 Evading immune surveillance as a mechanism of prostate cancer metastasis to bone   Nikola Baschuk         1345 Increased expression of the ETS1 transcription factor promotes epithelial-to-mesenchymal transition (EMT) in prostate cancer cells   Marc Thomas         1400 Tie-2 regulates stemness and metastasis of prostate cancer cells   Patrick Ling         1415 YB-1, a driver of prostate cancer progression   Anja Rockstroh         1435 MicroRNA-194 promotes migration and invasion of prostate cancer cells by regulating epithelial-

10

### Monday 1st September 2014

1530	Radical Prostatectomy State of the Art         Plenary 3         Chair: Peter Swindle, Tom Shannon         1530 Personal perspective on open and robotic prostatectomy           Peter Carroll         1545 Improving functional outcome after radical prostectomy           Markus Graefen         1600 Extended PLND-Technique, Patient Selection, and Results           John Davis         1615 Optimising outcomes of RARP through modular and Fellowship training – EHUS initiatives           Henk Van der poel         1630 Salvage radical prostatectomy post-focal and whole-gland HIFU           Paul Cathcart         1645 Robotic Surgery Simulation: The opportunities and the challenges           Jeff Berkley         1700 Discussion   Panel	Biomarkers and Diagnostics Room 218 Chair: Prof Judith Clements 1530 Circulating microRNAs as biomarkers and regulators of prostate cancer   <i>Luke Selth</i> 1545 A Novel Protein Biosensor for Early Prostate Cancer Diagnosis   <i>Masuda Nabi</i> 1600 Methylated glutathione s- transferase 1 (mGSTP1) as a potential plasma epigenetic marker of prognosis and response to chemotherapy in castrate-resistant prostate cancer (CRPC).   <i>Kate Mahon</i> 1615 Overexpression of ACSM1,CACNA1D and LMNB1, three novel biomarker candidates in prostate cancer   <i>Saeid Alinezhad</i> 1635 Loss of stromal androgen receptor in prostate cancer results in poor patient outcome by altering the composition of the extracellular matrix, leading to enhanced cancer cell migration and invasion	Latest exercise prescription for men with prostate cancer: Interactive Workshop Room 220 1530 Interactive workshop exploring the most up to date exercise prescription for men with prostate cancer Prof Rob Newton Prof Daviel Galvao Dr Prue Cormie Mark Trevaskis <b>Pre-registration required</b> Registrants are invited to wear exercise clothing
1730- 1830	Room 218 Chair: Lisa Horvath Changes in the clinical paradigm of adva Peter Carroll	Damien Leech	systemic agents   Janssen
1900- 2330	APCC 2014 Conference Dinner Mural Hall		





### Tuesday 2nd September 2014

0645	BREAKFAST SESSION Room 219 Chair: Nathan Lawrentschuk Bayer-sponsored breakfast session Sequencing of therapies in metastatic prostate cancer: how and when   Matthew Smith	BREAKFAST SESSION Room 220 Sanofi-sponsored breakfast session The Genomic Era of Translational Medicine   Prof Vanessa M. Hayes
0755-	Combined Multidisciplinary Plenary Plenary 3 Chair: Scott Williams, John Yaxley 0755 Welcome   <i>Chair</i> 0800 Screening for prostate cancer: Do the U.S. Preventive S <i>Mitchell Benson</i> 0815 Genomic Classifiers for Prostate Cancer – How to Evalu 0830 Androgen receptor DNA binding profiling in prostate can 0845 MSH2, prostate cancer and Lynch syndrome: a mismate 0900 Minimising the harms of androgen deprivation therapy 0915 Standardisation of assay methods limits variability of to 0930 Low dose rate prostate brachytherapy as a boost or mon <i>Crook</i> 0945 Discussion   <i>Panel</i> 0955 Message from Principal Sponsor AstraZeneca   <i>Christo</i> ,	ncer   Henk Van der Poel ch made in Hell?   Chris Hovens   Bertrand Tombal tal PSA measurements   Thomas Lynch notherapy: long term results that are hard to beat   Juanita
1000- 1030	MORNING TEA	
1030- 1230	CRPC Changing Paradigms         Plenary 3         Chair: Daniel Moon, Shahneen Sandhu         1030 Prevention and treatment of bone metastases in prostate cancer   Matthew Smith         1045 Timing and modalities of AR targeted agents during early CRPC   Bertrand Tombal         1100 The Urologist's role in the treatment of castrate resistant prostate   Mitchell Benson         1115 Patient selection for abiraterone – who is most likely to respond?   Arun Azad         1130 How docetaxel fits in the changing landscape   Ben Tran         1145 CRPC case discussion   Panel         1220 Life in the Fast Lane – John Fitzpatrick remembered   Roger Kirby	Therapeutic Targets         Room 218         Chair: A/Prof Lisa Horvath         1030 Monoterpene glycoside, ESK246, targets LAT3- mediated amino acid transport and cell growth in prostate cancer   <i>Qian Wang</i> 1045 Investigating the PI3K pathway in prostate cancer   <i>Helen Pearson</i> 1100 PTRF decreases prostate cancer angiogenesis potential   <i>Zeyad Nassar</i> 1115 Elucidating the molecular action of synthetic heat shock protein 90 inhibitors in prostate cancer   <i>Heather Armstrong</i> 1130 Inhibition of fatty acid synthase suppresses androgen signaling in LNCaP cells   <i>Martin Sadowski</i> 1145 Androgen receptor influences the proliferation of prostate cancer cells through exosomes   <i>Carolina Soekmadji</i> 1205 Feasting in a time of famine – mechanisms of metherine resistence   <i>Martin Sadowski</i>
		castration resistance   Niall Corcoran

### Tuesday 2nd September 2014

High-risk non-met Plenary 3	Prostate Cancer Genetics and Epigenetics	
Chair: Henry Woo, James McKean         1330 Management of high-risk, non-metastatic prostate         cancer – are all options truly equivalent?   Peter Carroll         1350 The evolution of HDR prostate brachytherapy: has it         come of age?   Juanita Crook         1405 PLND & Fluorescence guided sentinel node imaging         for prostate cancer   Henk van der Poel         1420 Management of High Risk Prostate Cancer – MD         Anderson approach   John Davis         1435 Is intraoperative Choline Positron Emission         Tomography (PET) during robotic prostatectomy ready for         PRIME time use: introducing the PRIME study           Paul Cathcart         1450 Vancouver approach to very high-risk prostate cancer         Joe Ischia	Room 218         Chair: Dr Niall Corcoran         1330 Intra-metastatic heterogeneity and treatment-induced remodelling of subcional architecture of lethal prostate cancer   Chris Hovens         1345 Functional analysis of the KLK3 variants, found to be associated with prostate cancer risk   Srilakshmi Srinivasan         1400 Association and functional analysis of miRSNP in prostate cancer – results from the large collaborative oncological genetics studies (COGS)   Jyotsna Batra         1415 Identification of candidate functional short tandem repeats for analysis in large case-control prostate cancer risk studies.   John Lai         1430 Macrophage inhibitory cytokine-1 (MIC-1/GDF15) gene deletion is associated with increased tumor growth in TRAMP prostate cancer-prone mice.   Yasmin Husaini         1445 Genomic analysis of circulating tumor DNA in plasma of metastatic castration-resistant prostate cancer patients treated with abiraterone acetate and enzalutamide   Arun Azad         1505 Significance of ethnic-based disparities in prostate cancer risk and outcomes   Vanessa Hayes	
AFTERNOON TEA		
Looking after men post-treatment         Plenary 3         Chair: David Winkle, Phil Dundee         1530 Prostate Cancer Survivorship – improving outcomes   Matthew Smith         1545 The role of exercise in improving outcomes and quality of life for men with metastatic prostate cancer   Rob Newton         1600 The impact of surgery on erectile function and how to help men recover function   Chris Nelson         1615 Testosterone Replacement Therapy: How safe is it?   Larry Goldenberg         1630 PROSTMATE – an online platform enabling survivorship care   Addie Wootten         1645 Discussion   Panel         1655 Meeting close   Tony Costello		
	Chair. Henry Woo, James McKean         1330 Management of high-risk, non-metastatic prostate         cancer – are all options truly equivalent?   Peter Carroll         1350 The evolution of HDR prostate brachytherapy: has it         come of age?   Juanita Crook         1405 PLND & Fluorescence guided sentinel node imaging         for prostate cancer   Henk van der Poel         1405 Management of High Risk Prostate Cancer – MD         Anderson approach   John Davis         1435 Is intraoperative Choline Positron Emission         Tomography (PET) during robotic prostatectomy ready for         PRIME time use: introducing the PRIME study           Paul Cathcart         1450 Vancouver approach to very high-risk prostate cancer         Joe Ischia    AFTERNOON TEA      AFTERNOON TEA    Looking after men post-treatment    Plenary 3 Chair: David Winkle, Phil Dundee 1530 Prostate Cancer Survivorship – improving outcomes and quality 1600 The impact of surgery on erectile function and how to h 1615 Testosterone Replacement Therapy: How safe is it?   L 1630 PROSTMATE – an online platform enabling survivorship 1645 Discussion   Panel	

1700 CONFERENCE CONCLUDES

## Zero in on Stand 29

Visit Stand 29 to learn about our focus on metastatic castration resistant prostate cancer and see how Janssen is caring for the world one person at a time



Janssen-Cilag Pty Ltd, ABN 47 000 129 975, 1-5 Khartoum Road, Macquarie Park NSW 2113 AU-ZYT0223 EMVZYT1047 Date prepared July 2014.





# abbvie


AbbVie Pty Ltd. ABN 48 156 384 262. 32-34 Lord Street, Botany NSW 2019. Ph: 1800 043 460

Page 18

#### Janssen Satellite Symposium Changes in the clinical paradigm of advanced prostate cancer in light of emerging systemic agents

Date:	Monday 1st September 2014		
Time:	17:30 – 18:30 (refreshments from 17:15)		
Location:	Melbourne Convention Centre		
Chairs:	Dr Lisa Horvath		
Speakers:	Dr Peter Carroll		
The real world management of			

patients with prostate cancer







Dr Peter Carroll Dr. Peter Carroll received his undergraduate training at the University of California, Berkeley. After graduating with honors from Georgetown University School of Medicine, he came to UCSF for his general surgery training and urology residency. He completed a fellowship in Urologic Oncology at Memorial-Sloan Kettering Cancer Center before returning to join the faculty in the Department of Urology at UCSF.



### Posters Clinical Urology

	0,	
7	Inguinal Hernia Rates After Robot-Assisted Radical Prostatectomy: Our 5-year Experience at Singapore General Hospital	Weber Lau
18	The oncological outcomes of robotic assisted radical prostatectomy in an unscreened multi-racial Asian population	Alvin Wei Xiang Low
23	Emerging Trends in the Terminology of Prostate Cancer Treatment	Jonathon Lo
32	Transrectal Ultrasound-Guided Prostate Biopsy Sepsis: A Worldwide Literature Review On Rates, Risk Factors And Prophylaxis	Elliot Anderson
33	The cost of management for patients with metastatic prostate cancer in New Zealand	Chunhuan Lao
40	Oncological Outcomes of Robotic Prostatectomy in the Victorian Public Sector	Niranjan Sathianathen
42	Prostate Cancer Registry (PCR) quality of life outcomes following prostate cancer treatment	Jeremy Millar
43	Satisfaction and Regret following RALP may not always reflect continence and erectile function	Milan Thomas
51	Transitional experience from pure laparoscopic to robotic-assisted radical prostatectomy: An Australian single surgeon series	Daniel Moon
54	Influence of variation in use of radical therapy on risk-adjusted prostate cancer mortality in England and the $\ensuremath{US}$	Paul Cathcart
58	Comparison of Short Term Oncological and Functional Outcomes between Open and Robotic-Assisted Radical Prostatectomy for Localized Prostate Cancer in the Victorian Prostate Cancer Registry	Wee Loon Ong
59	Extended thromboembolism prophylaxis post open radical prostatectomy is safe and effective	Daniel Chen
65	Incontinence after prostatectomy is related to urethral mechanics observed with transperineal ultrasound imaging	Ryan Stafford
69	Proton beam therapy websites: Characteristics and claims	Sarah O'Neill
70	Practice patterns and perioperative outcomes of radical prostatectomy in Victoria: A comparison of open, laparoscopic and robotic prostatectomy in 5130 patients over 3 years	Niranjan Sathianathan
72	A health economic analysis of robotic surgery in the Australian public health system	Niranjan Sathianathan
73	No difference on overall survival rate between patients with prostate cancer who underwent surgical hormonal therapy and medical hormonal therapy	Untung Tranggono
77	Pathways of care for metastatic prostate cancer patients in the Midland Cancer Network, New Zealand	Ross Lawrenson
32	Prevention of symptomatic skeletal events in patients with genitourinary tumours and bone metastases treated with denosumab or zoledronic acid	Kenneth Pittman
34	Treatment for localized prostate cancer in New Zealand men in light of clinical guidelines	Zuzana Obertova
35	The burden of skeletal-related events (SREs) on pain outcomes in patients with castration-resistant prostate cancer (CRPC) and bone metastases	Matthew Smith

### Posters continued Clinical Urology

87	Prostate Volume Estimation in Prostate Cancer: Are Urologists or Radiologists More Accurate?	Steffi Yuen
88	Transrectal ultrasound-guided biopsy with anterior needles improves detection and localisation of prostate cancer in men undergoing active surveillance	Arveen Kalapara
91	Does sparing the neurovascular bundle affect urinary continence outcomes in men undergoing radical prostatectomy? A Systematic Review	Fairleigh Reeves
94	The utilisation of Active Surveillance in a Victorian cohort of men, according to PRIAS and other contemporary Active Surveillance protocols	Mahesha Weerakoon
107	Current use of Active Surveillance in Victoria, Australia: a patterns of care analysis from the Prostate Cancer Registry	Mahesha Weerakoon
108	Clinical use of a novel technique for ablation of prostate cancer, irreversible electroporation (IRE), and characterisation of the resulting prostate pathology	Jeremy Millar
110	The APCCR: beginning a global journey towards international benchmarking of prostate cancer outcomes	Sue Evans
113	Validation of the relationship between urethral motion measured with transurethral ultrasound imaging and activation of the striated muscle complexes of the male pelvic floor	Paul Hodges
118	Stereotactic body radiotherapy for oligometastatic prostate cancer: Retrospective series from a single Australian centre	Fairleigh Reeves
128	Biological imaging for focal brachytherapy for prostate cancer	Scott Williams
131	Surgical outcomes of patients who fail active surveillance for localised prostate cancer in an Australian population	Arveen Kalapara
139	Prostate cancer in the elderly in Morocco: a retrospective review	Hinde Hami
141	Prostate cancer in Niger: first results from a population-based cancer registry	Hinde Hami
143	Results of surgical treatment of patients with clinically insignificant prostate cancer classified according Epstein criteria	Kirill Nyushko
144	Outcome prognostic factors in prostate cancer patients after surgical treatment	Kirill Nyushko
158	Practice patterns of urologists in managing Korean males 40 years old or younger with high serum PSA levels	Dae-Seon Yoo
160	An initial Melbourne experience of multiparametric MRI for the diagnosis of prostate cancer	Sarah O'Neil
161	Does transperineal biopsy cause erectile dysfunction?	Jeremy Grummet
162	Radical prostatectomy without prostate biopsy in PIRADS 5 lesion on 3T multi- parametric MRI of the prostate gland: 2 Case Reports	Andrew Keller
167	Zero sepsis in 452 consecutive transperineal biopsies: an update on the VTBC database	Jeremy Grummet
172	Evaluation of models predicting insignificant prostate cancer to select men for active surveillance of prostate cancer	Lih-Ming Wong
173	A comparison of two novel methods of analgesia for transrectal ultrasonography (TRUS)-guided prostate biopsy – Penthrox alone versus Penthrox plus periprostatic infiltration of local analgesia	Sean Huang



### Posters continued

### Nursing & Allied Health

10	Working with Grieving Adults: The Relevance of Attachment to Coping Styles	John Toussaint
17	Trajectory of pain following open and minimally invasive radical prostatectomy for localised prostate cancer: An Australian multi-site, comparative study	Damien Khaw
19	Baseline characteristics of the participants in a telephone-delivered mindfulness intervention for men with advanced prostate cancer	Robert McDowall
20	Preliminary results of My Road Ahead: An online psychological intervention for men with prostate cancer	Addie Wootten
22	Effects of a clinician's referral and physical activity program for men who have completed treatment for prostate cancer: A multicentre cluster randomized controlled trial [ENGAGE]	Patricia Livingston
24	Evaluation of the Outreach Clinics of the Prostate Cancer Specialist Nurse in Tamworth, NSW	Sharon Slack
31	PROSPECT: Understanding how multiple factors interact to predict depression in prostate cancer patients and their partners during the first year after diagnosis	Chris Sharpley
34	Are current definitions of depression inadequate for prostate cancer patients?	Vicki Bitsika
36	Engaging Men with Prostate Cancer: The development of a tumour specific Living with Cancer Education Program	David Gray
38	Rethinking the DRE: Introducing novel non-invasive tests of pelvic floor muscle function in humans	Jo Milios
45	Self esteem, body image, sexual and urinary function of gay and straight prostate cancer survivors: Is there really a difference?	Christopher Thomas
46	Designing New Health Services for Advanced Prostate Cancer Patients: Challenges and Opportunities	Amol Wagholikar
47	The prevalence of depressive symptoms among patients undergoing low and high dose-rate brachytherapy for prostate cancer	David Christie
63	Reduced unmet supportive care needs after implementation of a prostate cancer specialist nursing service	Julie Sykes
64	Improving Patient Outcomes In Robotic Prostatectomy Patients Using A Nurse-Led Clinic	Emma Birch
66	Reduction of fatigue in men on ADT for prostate cancer: effect of varying exercise modes	Dennis Taaffe
78	Prostate cancer: Impact on quality of life for a cohort of New Zealand men	Charis Brown
81	Building systematic access to psychological services for men with prostate cancer	Tessa Jones
98	Psychological Distress and Advanced Prostate Cancer	Leah Zajdlewicz
111	Maximal exercise testing of men with prostate cancer being treated with ADT	Robert Newton
114	Establishment and evaluation of a multidisciplinary complex prostate cancer clinic	Helen Crowe

### Posters continued

### Nursing & Allied Health

120	The efficacy of a clinician referred exercise training program on markers of cardiometabolic risk for prostate cancer survivors	Patrick Owen
130	Engaging Men with Prostate Cancer: The evaluation of a tumour specific. Living with Cancer Education Program	David Gray
150	Pre-operative Pelvic Floor Muscle Training: a Review	Melissa Martin
152	Using web-enabled technology to support men with prostate cancer	Addie Wootten
156	The efficacy of a clinician referred supervised exercise training program on fitness, body composition and physiological outcomes for prostate cancer survivors	Steve Fraser
163	Validation of a Nurse Led Robotic Prostatectomy Patient Pathway	Emma Birch
164	Pelvic Floor muscle contraction with verbal instruction- do men get it?	Patricia Neumann
174	Development and testing the acceptability of Rekindle, a web-based psychosexual resource for all cancer survivors and their partners	Zac Seidler
175	Qualitative experiences of patients with incontinence	Sarah Woollet



### da Vinci Xi

The Next Frontier for Minimally Invasive Surgery



AUSTRALIA P:1300 DEVICE (338 423) E: customers@device.com.au ww.device.com.au NEW ZEALAND P: 0508 338 423 E: sales@device.co.nz www.device.co.nz



### Posters continued

### Translational Science

6	PTRF decreases prostate cancer angiogenesis potential	Zeyad Nassar
11	Repositioning "Old" Drugs for New Causes: Identifying New Treatments for Metastatic Prostate Cancer	Esha Shah
13	Overexpression of ACSM1,CACNA1D and LMNB1, three novel biomarker candidates in prostate cancer	Saied Alinezhad
29	Circulating microRNAs associated with docetaxel chemotherapy outcome of prostate cancer	Hui-Ming Lin
30	Characterisation of ADAMTS-15: a potential tumour suppressor gene in Prostate cancer	Marley Binder
44	Disrupting caveolae promotes malignant behaviour in normal prostate cells	Jin Yih Low
48	Monoterpene glycoside, ESK246, targets LAT3-mediated amino acid transport and cell growth in prostate cancer	Qian Wang
60	3D Bone Marrow Metastatic Prostate Cancer Niche Mimic	Eman Mosaad
80	Relative cytotoxic potencies of alpha1-adrenoceptor antagonists on PC3 and LNCap prostate cancer cells	Amanda Forbes
99	Challenges and Opportunities in Establishing Biobanking from a Body Donor Program	Allison Eckert
112	YB-1, a driver of prostate cancer progression	Anja Rockstroh
115	BDX1: A natural small molecule activator of the amino acid stress response pathway in prostate cancer cells	Michelle Liberio
116	Androgen receptor influences the proliferation of prostate cancer cells through exosomes	Carolina Soekmadji
117	The ascidian natural product EB activates DNA damage response pathways through inhibition of topoisomerase II in LNCaP cells	Michelle Liberio
123	Mechanism of action studies in prostate cancer cells on new compounds isolated from an Australian endemic rainforest tree	Claire Levrier
124	Targeting neuropilin-1 to inhibit prostate cancer metastasis and therapy resistance	Brett Hollier
127	Functional analysis of the KLK3 variants, found to be associated with prostate cancer risk	Srilakshmi Srinivasan
129	Association and functional analysis of miRSNP in prostate cancer - Result from the large collaborative oncological genetics studies (COGS)	Jyotsna Batra
132	Inhibition of fatty acid synthase suppresses androgen signalling in LNCaP cells	Martin Sadowski
133	Defining the effect of metformin treatment in androgen deprived prostate cancer cells	Jennifer Gunter
135	Androgen deprivation increases migration and invasion in prostate cancer cells and is increased by insulin	Phoebe Sarkar
137	Clinical Studies at the Australian Prostate Cancer Research Centre Queensland	Maggie Fung
168	Australian Prostate Cancer BioResource, 2014	Trina Yeadon

### **Clinical Urology Meeting**

Following on the huge success of the Prostate Cancer World Congress in 2013, the Clinical Urology Stream at the 2014 Asia-Pacific Prostate Cancer Conference promises to raise the bar further again. The Melbourne Consensus Statement on the Early Detection of Prostate Cancer attracted worldwide attention upon its release at the 2013 meeting subsequent peer-review publication in the BJUI recently. This year, we again plan to leverage off the presence of so many world-leading prostate cancer experts to answer some of the key guestions challenging us in clinical practice today. Our International Faculty contains a multidisciplinary mix of experts from the world of urology, medical oncology, radiation oncology, translational science, nursing and allied health, and will address some of the most pressing areas in prostate cancer today including:

- Diagnosis, staging & risk stratification
- Advances in MRI and other imaging
- Active surveillance
- · Radical prostatectomy improving outcomes
- Castrate resistant prostate cancer the changing paradigm
- Advances in radiation oncology

In addition to the keynote addresses in the main plenary, we will present breakfast sessions, satellite sessions, specialist workshops and the 4th da Vinci Prostatectomy Masterclass.

We look forward to presenting another outstanding Clinical Urology Program at APCC 2014 and we thank you for your support.



Co Convenor Professor Tony Costello President, 15th Asia-Pacific Prostate Cancer Conference



Co Convenor Associate Professor Declan Murphy Convenor, Clinical Urology

#### Thank you to the support of our sub Committee Members

**Dr Ben Tran** Royal Melbourne Hospital, Melbourne A/Prof Scott Williams Peter McCallum Cancer Centre, Melbourne The Asia-Pacific Prostate Cancer Conference program has been reviewed by the Genitourinary Oncology Special Advisory Group (SAG) of the Urological Society of Australia and New Zealand. The following CPD pints have been confirmed:

Monday 1 September: 7 hours

Tuesday 2 September: 7 hours

Additional Breakfast Session Tuesday 2 September: 1 hour

Total CPD points for the full meeting: **14 points** 

Total CPD points for the full meeting including breakfast session Tuesday 2 September: 15 points

da Vinci Masterclass Sunday 31 August: **7 hours** 

LDR Brachy Masterclass Sunday 31 August: 5 hours

Prostate MRI Imaging & Biopsy Masterclass Sunday 31 August: 5 hours

in Category 4: Maintenance of Clinical Knowledge and Skills

### Clinical Urology Breakfast

#### Tuesday 2 September 2014 0645 – 0745

Sequencing of therapies in metastatic prostate cancer: how and when **Dr Matthew Smith** 

Sponsored by Bayer



### Nursing & Allied Health

The Nursing and Allied Health stream showcases the most relevant information and education across the disciplines of nursing, psycho-oncology, continence practitioners and exercise physiology. This year these disciplines will join together to offer a comprehensive multidisciplinary approach to prostate cancer care in a full day program. The Nursing & Allied Health program will highlight how the professional expertise of these disciplines using a multi-disciplinary approach can enhance existing prostate cancer management and provide the best care for patients and their partners and families.

Sunday 31st August will provide a comprehensive multidisciplinary series of sessions focussed on the care of men with prostate cancer across all stages of the disease. The opening session will focus on continence management, the second session will provide a multidisciplinary overview of active surveillance, the third session will explore the challenges of hormonal therapy and the final session of the day will provide an insight into the complexities of advanced and metastatic prostate cancer.

Monday 1st September will showcase the best research submitted for presentation in the nursing and allied health stream with a full session dedicated to original research presentations. Posters of submitted abstracts will also be on display for the entire conference period so please make sure you explore the fantastic work being conducted. On Monday afternoon an interactive exercise workshop will be presented by leading exercise physiology researchers from Edith Cowan University. This session will provide a hands-on experience of the latest evidence in exercise prescription for men with prostate cancer.

Highlights of the program include our international guest speaker, Dr Christian Nelson, Clinical Psychologist from Memorial Sloan Kettering Cancer Centre in New York; and the interactive exercise workshop led by the expert exercise physiologists Prof Robert Newton, Dr Prue Cormie, Prof Daniel Galvao and Mark Trevaskis.





Co Convenor Ms Helen Crowe Urology Nurse Practitioner, Research Nurse, Epworth Prostate Centre

Helen has been working in urology for over 20 years, and was instrumental in establishing urology nursing professional organisations in Australia. She is employed in a private urology practice, devoted to prostate cancer, as a Nurse Practitioner and at Epworth Prostate Centre as a research nurse. She has presented nationally and internationally, published and won awards for her work on the nursing management of men with prostate cancer.



#### Co Convenor Dr Addie Wootten

Clinical Psychologist, Department of Urology, The Royal Melbourne Hospital. Director of Clinical & Allied Health Research, Epworth Prostate Centre, eHealth Research Manager, Australian Prostate Cancer Research

Dr Addie Wootten is a clinical psychologist who specialises in the area of prostate cancer. Dr Wootten is the eHealth research manager at Australian Prostate Cancer Research; the director of clinical and allied health research at the Epworth Prostate Centre and also works in the department of urology at The Royal Melbourne Hospital.

### Nursing & Allied Health

#### Thank you to the support of our Sub Committee Members



**Dr Jane Crowe** Private General Practitioner & Prostate Cancer Physician, Epworth Prostate Centre

Jane has worked over 20 years in General Practice in the Eastern suburbs of Melbourne. In 2011 Jane started work as a Prostate Cancer Physician, part time, at the Australian Prostate Cancer Research Centre, (Epworth) where she sees men with Advanced Prostate Cancer and manages and monitors the effects of hormone therapy and provides chronic disease management. Jane is also involved with Prostate Cancer Research, with a particular interest in Prostate cancer management in primary care.



Ms Kay Talbot Practice Manager/RN Australian Urology Associates

Kay is Practice Manager at Australian Urology Associates and has been involved in Urological nursing for many years. She has special interests in prosthetics in urology & nursing education. She was a founding member of the Victorian Urological Nurses Society, and the Australia and New Zealand Urological Nurses Society. Kay has been an invited speaker at numerous state and national education meetings, has several publications, and has received a number of awards associated with her interests in urological nursing care.



**Ms Shan Morrison** Women's and Men's Health Physiotherapy

Shan is a fellow of the Australian College of Physiotherapists and has post graduate qualifications in Continence and Pelvic Floor Rehabilitation. She has over 20 years of experience and is the Director of Women's and Men's Health Physiotherapy, a Victorian private practice which specialises in managing female and male pelvic floor disorders. She has a particular interest in the prevention and management of incontinence pre and post prostatectomv.



Prof Robert Newton Edith Cowan University

Professor Rob Newton is Foundation Professor in Exercise and Sports Science at Edith Cowen University Health and Wellness Institute, Perth, Western Australia. Current clinical and research directions include: exercise medicine for reducing decline in strength, body composition and functional ability in cancer patients; ADT toxicities; management of lymphedema.

#### Latest exercise prescription for men with prostate cancer

Date: Monday 1 September Time: 15:30 – 17:00 Location: Melbourne Convention Centre

Learn from the leaders in exercise interventions for men with prostate cancer. Prof Rob Newton, Prof Daniel Galveo, Dr Prue Cormie and Mark Trevaskis from Edith Cowan University will lead this interactive workshop that will fully equip you with the knowledge needed to advise your prostate cancer patients about the benefits of exercise.

The ESSA Professional Development Committee certifies that this Professional Development offering meets the criteria for 2 Continuing Professional Development (CPD) Points.





#### Nursing and Midwifery Board of Australia

Continual Professional Development Registration Standard

One hour of active learning will equal one hour of CPD. It is the nurse or midwife's responsibility to calculate how many hours of active learning have taken place. If CPD activities are relevant to both nursing and midwifery professions, those activities may be counted in each portfolio of professional development.

Full attendance at this APCC 2014 offers 10.5 hours of nursing education.

### Translational Science Program

The translational science meeting brings together leading prostate cancer researchers, linking research from basic, translational and clinical researchers to improve outcomes for patients. Sessions will be themed-based and cover the following areas:

#### **New Therapies**

From "old" drugs through to newly isolated natural products, this session will explore novel targeted therapies for prostate cancer, biomarkers of treatment response, inhibition of metastasis and treatment resistance.

### Metastasis, Progression and Biomarkers

The mechanisms responsible for prostate cancer cell dormancy, growth and metastasis will be explored in this session. Themes include immune surveillance, promoters of migration and invasion and the role of androgen receptor. The session will also explore new biomarkers for diagnosing, assessing, and monitoring the treatment response of prostate cancer, and how these biomarkers could influence clinical outcomes.

#### **Therapeutic Targets**

The ability of prostate cancer cells to survive, proliferate, migrate and invade provides targets for future therapies. This session explores a number of potential targets for therapeutic intervention.

#### Prostate Cancer Genetics and Epigenetics

This session presents a number of genetic risk factors associated with prostate cancer, and an in-depth analysis of the genomic and epigenetic changes associated with prostate cancer progression, recurrence and metastases.



Co-Convenor Dr David Sandall Chief Operating Officer, Epworth Prostate Centre, Melbourne Australia

David brings experience in managing both academic research programs and R&D projects in the pharmaceutical industry



Co-Convenor Prof John Mills Is an internationallyrecognized physicianscientist with several research interests including prostate cancer.

He is the Director of Research & Development at TissuPath Specialist Pathology, among other appointments, and he was Chair of the Prostate Cancer Foundation of Australia (PCFA) Research Program from 2007 to 2013



### Masterclasses





### MASTERCLASS

### 4th da Vinci<sup>®</sup> Prostatectomy Masterclass

This event has attracted large numbers of delegates in recent years to hear from world experts in robotic-assisted surgery and has proved one of the most highly-rated parts of the Program. The rapid growth in installation and procedure numbers since 2011 has led to a doubling in the number of systems available and a huge increase in the number of urologists transitioning to robotic-assisted surgery. This Masterclass remains the premium event for surgeons at all levels to hear from the best in the world and to improve their techniques.

This year we have assembled a hugely-experienced faculty of robotic surgeons to deliver an outstanding program for those interested in robotic-assisted radical prostatectomy using the da Vinci© surgical system. Dr Henk Van Der Poel (NKI, Amsterdam), Dr John Davis (MD Anderson, Texas) and Dr Markus Graefen (Martini Clinic, Hamburg) are worldleading experts in robotic cancer surgery and will lead the faculty in an all-day Masterclass focusing this year on more advanced aspects of the procedure. Urologists of all levels from trainee to experienced robotic surgeon will benefit from this interactive and video-based da Vinci Prostatectomy Masterclass.

#### Highlights include:

- Full-length da Vinci
   radical prostatectomy and extended PLND (Henk Van Der Poel), including fluorescence-guided sentinel node dissection
- Creating Spaces technical tips for difficult situations (John Davis)
- Urethral dissection, apex preparation & frozen section biopsy tips for maximizing functional outcomes (Markus Graefen)
- Video-based tutorials of difficult cases
- Full schedule to be confirmed

In addition, a da Vinci© Si with simulator will be available all day in the trade area.

Convenors



Dr Geoff Coughlin



Dr Daniel Moon



Associate Professor Declan Murphy

Program 8:30 – 10:30	SESSION 1 Chairs: Geoff Coughlin and Daniel Moon Unedited case - High risk prostate cancer   <i>Henk van der poel</i> Evidence for RARP – key robotic surgery publications from 2013-14   Simon van Rij
10:30 - 11:00	Morning tea
11:00 - 12:30	SESSION 2 - Maximising Functional Outcomes Chairs: Peter Sutherland and Justin Peters Bladder neck preservation   <i>Markus Graefen</i>
11:20 - 12:10	Nerve-sparing in 2014 – how I do it   Henk van der poel, John Davis, Geoff Coughlin
12:10 - 12:30	Managing urethra/apex   Markus Graefen
12:30 - 13:30	Lunch
13:30 - 15:00	SESSION 3 - Tips and Tricks "Creating spaces" Chairs: John Yaxley and Laurence Harewood John Davis
15:00 - 15:30	Afternoon tea
15:30 - 17:00	SESSION 4 - High risk prostate cancer Chairs: David Bouchier-Hayes and Nathan Lawrentschuk
15:30 - 16:00	Extended pelvic lymphadenectomy   John Davis
16:00 - 16:20	Sentinel nodes   Henk van der Poel
16:20 - 16:50	Salvage RARP post HIFU/focal therapy - UCL Experience   Paul Cathcart
16:50 - 17:00	Discussion



#### MASTERCLASS

### Prostate MRI Imaging & Biopsy Masterclass

The use of MRI scanning for the diagnosis and staging of prostate cancer has become an area of considerable interest. The increased availability of 3T magnets and appropriate expertise has led to increased use of this modality. Improved image quality has also led to the use of multiparametric MRI images as part of a fusion-guided ultrasound approach to prostate biopsy.

To improve our knowledge in this area, we are presenting a Prostate MRI Imaging & Biopsy Masterclass led by Professor Jelle Barentsz, Professor and Head of Prostate Imaging at the Rabdoud University Medical Centre in the Netherlands. Professor Barentsz is the world's leading authority on prostate imaging using multiparametric MRI and has been a pioneer in the use of standardized reporting methodology (PIRADS) and also in the use of image-guided biopsy.



Co-Chair

A/Prof Stefan Heinze Deputy Director of Radiology, Royal Melbourne Hospital Stefan learnt prostate MRI with professor Hedvig Hricak at Memorial Sloan Kettering Cancer Center as part of a Body Imaging Fellowship.

He established the prostate MRI service at the Royal Melbourne Hospital and is involved in teaching prostate imaging. He is published in peer-reviewed journals and has presented widely at local and national meetings on prostate imaging.



#### Co-Chair Dr Peter Swindle MBBS MS FRACS

Dr Peter Swindle is a urologist who specialises solely in prostate cancer. His expertise lies in robotic prostatectomy and he has a special interest in MRI of the prostate.

Dr Swindle trained in Queensland and subsequently completed a Masters of Surgery at the University of Sydney on magnetic resonance of the prostate. He then undertook a 2 year subspecialty Fellowship at Memorial Sloan-Kettering Cancer Centre in New York focusing on prostate cancer and undertook 2 years research on MRI of the prostate. He also completed an American Brachytherapy Fellowship at the Seattle Prostate Institute.

He has a research appointment at the Mater Medical Research Institute as well as clinical appointments at the Mater Private Hospital, Mater Adults Hospital, Greenslopes Private Hospital and the Wesley Hospital.

#### Program

10:00 - 10:05	Welcome / Course overview   Declan Murphy, Stephan Heinze
10:05 - 10:35	Lecture   Jelle Barentez
10:35 - 11:00	CADSTREAM orientation & How I report a prostate MRI   Stephan Heinze
11:00 - 11:30	Workstation based case review   Self-review
11:30 - 11:45	Case review with faculty   All faculty
11:45 – 12:30	Workstation based case review   Self-review
12:30 - 12:45	Case review with faculty   All faculty
12:45 - 13:30	Lunch
13:30 - 14:00	Lectures   Peter Swindle
14:00 - 15:00	Workstation based case review   Self-review
15:00 – 15:15	Afternoon Tea
15:15 - 15:30	Problem cases review with faculty   All faculty
15:30 - 16:00	Lecture and Closing comments   Jelle Barentez, Stephan Heinze

#### MASTERCLASS

## Focal therapy: the role of LDR & HDR brachytherapy

The aim of this masterclass is to bring together experts in the field of brachytherapy, focal therapy, imaging and pathology to present the evidence for developing a focal brachytherapy program. The workshop will include discussions on focal therapy alone for early low risk prostate cancer, focal boosts in whole gland monotherapy and salvage of focal recurrences.

#### Workshop aims

- To introduce the concept of focal distribution of cancer in the prostate,
- To review the evidence for imaging modalities to identify significant focal lesions,
- To explore the role of brachytherapy in delivering focal therapy.

#### Who should attend

All those having an interest in the management of prostate cancer:

- Radiation oncologists
- Urologists
- Radiologists
- Physicists
- Radiation therapists

#### Program

10:30 - 11:10	The evidence for focal therapy A/Prof Juanita Crook, University of British Columbia, BCCA Center for the Southern Interior
11:10 – 11:30	Pathology and natural history of prostate cancer Dr David Clouston, Anatomical Pathologist, TissuPath
11:30 – 12:30	MRI for focal brachytherapy Dr James MacKean, Radiation Oncologist, & Dr John Yaxley, Urologist, Genesis Cancer Care, The Wesley Hospital, Brisbane
12:30 – 13:30	Lunch
13:30 - 14:00	Co-registration of imaging studies, the pros and cons of rigid vs. deformable registration A/Prof J Crook
14:00 - 14:20	Is there a gap in health care in Australia that focal brachytherapy can fill? A/Prof Jeremy Millar, Director, Radiation Oncology, WBRC & WBRG, Alfred Health
14:20 - 15:00	Treatment options for focal therapy A/Prof Nathan Lawrentschuk, U. Melbourne, Dept of Surgery and Ludwig Institute for Cancer Research, Austin Hospital and Peter MacCallum Cancer Centre
15:00 – 15:30	Afternoon tea
15:30 – 16:00	Treatment response following focal therapy, when do we know we have succeeded? A/Prof Scott Williams, Radiation Oncology, Peter MacCallum Cancer Centre, U. Melbourne
16:00 – 17:00	Are we ready for a focal brachytherapy trial in the Asia-Pacific Region? Proposer: Dr Ana Fernandez-Ots Discussant: A/Prof Juanita Crook Panel discussion: A/Prof Juanita Crook, A/Prof Jeremy Millar, A/Prof Nathan Lawrentschuk, Dr David Clouston, Dr James MacKean, Dr John Yaxley, A/Prof Scott Williams, A/Prof Annette Haworth

#### Faculty

A/Prof Juanita Crook A/Prof Jeremy Millar A/Prof Nathan Lawrentschuk Dr David Clouston Dr James MacKean Dr John Yaxley A/Prof Scott Williams A/Prof Annette Haworth



### Social Program

### Welcome Reception and Poster View Session

Date:	Sunday 31 August, 2014	
Time:	5.00pm – 7.00pm	
Venue:	Melbourne Convention	
	Centre, Ground Floor	

Cocktail drinks and canapés will be served in the Exhibition Space on ground level.

Delegates are welcome to roam the exhibition and see the latest research in all areas of Prostate Cancer. Talk one on one with presenters about their work.

Prizes will be awarded in each of the following categories:

- Clinical Urology
- Translational Science
- Nursing & Allied Health

#### **Conference Dinner**

	Monday 1 September, 2014
	7:00pm – 11:30pm
	Mural Hall, Myer
	Lounge Suit
Venue:	Mural Hall, Myer

Take one step inside Mural Hall and you will be transported to another world. Perhaps it is the Parisian inspiration, the parquet flooring or the 18th century style mirrored commodes that dance light around the room, that create the illusion that you are celebrating in a lavish European ballroom. Or perhaps it's because you are.

#### **Getting There:**

Coach transfers will depart from the Melbourne Convention Centre (South Wharf Entrance) following the Janssen Satellite Symposium



#### **Directions:**

- Enter via Postal Lane off
   Little Bourke Street
- A Mural Hall Staff member will be at the entrance with a sign to direct you
- Take the lifts to Level 6



### **Registration Information**

#### Consultant/Trainee/ Registrar/Fellow Full Registration includes:

- Entry to all conference sessions (Sunday Tuesday)
- Morning and Afternoon Teas and Lunch Daily
- Attendance to either the da Vinci Masterclass or LDR Brachytherapy Masterclass (Sunday 31 August)
- Attendance at the Welcome Reception & Poster Viewing (Sunday 31 August)
- Entry into the Exhibition
  Area
- Delegate Satchel
- Final Program

#### Nursing & Allied Health Full Registration includes:

- Entry to all conference sessions (Sunday Monday)
- Morning and Afternoon Teas and Lunch Daily
- Attendance at the Welcome Reception & Poster Viewing (Sunday 31 August)
- Entry into the Exhibition Area (Sunday Monday)
- Delegate Satchel
- Final Program
- Option to purchase a conference upgrade to include Tuesday Conference attendance for an additional \$100.00

#### Scientist/Researcher/ Student/Post Doc Full Registration includes:

- Entry to all conference sessions (Monday Tuesday)
- Morning and Afternoon Teas and Lunch Daily
- Attendance at the Welcome Reception & Poster Viewing (Sunday 31 August)
- Entry into the Exhibition
   Area (Monday Tuesday)
- Delegate Satchel
- Final Program

### Day Registration includes:

- Entry to all conference sessions on day of Registration
- Morning and Afternoon Teas and Lunch on day of Registration
- Entry into the Exhibition
   Area on day of
   Registration
- Delegate Satchel
- Final Program
- Attendance at the Welcome Reception & Poster Viewing (Nursing & Allied Health Sunday Tickets Only)

#### Masterclass Only Registration includes:

- Entry to nominated
   Masterclass
- Morning and Afternoon Teas and Lunch on Sunday 31 August
- Entry into the Exhibition Area on Sunday 31 August
- Delegate Satchel
- Final Program
- Attendance at the Welcome Reception & Poster Viewing

#### Registration Desk Hours

The Registration Desk will be open during the following hours:

Sunday 31 August 07:00 - 17:30

Monday 1 September 07:00 - 17:30

Tuesday 2 September 06:45 - 16:00

### Presentation Information

#### Chairs and Session Moderators

Please ensure that you are available in your presentation room at least ten minutes prior to the start of the session.

#### **Oral Presentations**

It is important that all speakers upload their presentation in the Speakers' Preparation Room at least two hours prior to the commencement of their allocated session. Speakers who are presenting at an early morning session should check-in their presentation the day before their presentation. An audio visual technician will be available in the Speakers' Preparation Room to assist with this process.

#### Poster Presentations

Posters will be displayed from Sunday 31 August through to the conclusion of the Conference on Tuesday 2 September. Poster presenters must check-in at the Registration Desk prior to setting up their posters in the Trade area. The presenting author must be present at their poster during the Poster Session from 17:00 - 19:00 on Sunday 31 August.

#### Speakers' Preparation Room


The Speakers' Preparation room is adjacent to the Registration Desk in the foyer of the Melbourne Convention Centre and will be open during the following hours:


Sunday 31 August	0700 - 1730
Monday 1 September	0700 - 1730
Tuesday 2 September	0700 - 1530

Speakers are requested to load their presentation with the AV Technicians at the Speaker's Preparation room a minimum 2 hours prior to their scheduled presentation.

### Melbourne

#### Your Host City





#### Accommodation

#### Hilton Melbourne South Wharf

0

2

3

South Wharf (Conference Hotel) 2 Convention Centre Place, South Wharf

#### Crown Metropol

#### Melbourne

Cnr Clarendon Street and Whiteman Streets, Southbank

#### Crown Promenade Melbourne

Cnr Queensbridge and Whiteman Streets, Southbank

#### Travelodge Docklands

66 Aurora Lane, Docklands

Oaks on Market 60 Market Street, Melbourne 5

### **General Information**

#### Attendance Certificate

A certificate of attendance is available upon request post conference. Please see the staff at the registration desk or contact apcc2014@icms.com.au

#### Car Parking

Parking is available at the Melbourne Exhibition Centre and adjacent car parks.

#### Catering

All morning teas, lunches and afternoon teas during the conference are included in your registration fee and will be served in the Exhibition.

A separate buffet will be setup in the Exhibition to cater for delegates who require a special dietary meal.

#### Conference Office ICMS Pty Ltd

PO Box 170 Hawthorn VIC 3122 P: 1300 792 466 F: +61 3 9818 7111 E: apcc2014@icms.com.au



#### Liability Disclaimer

In the event of industrial disruption or other unforeseen circumstances the Conference Office, the Organising Committee and the Host Organisations accept no responsibility for loss of monies incurred by participants and /or accompanying persons. The Conference Office, the Conference Committee and the Host Organisations accept no liability for injuries/losses of whatever nature incurred by participants and/or accompanying person, nor for loss or damage to their luggage and/or personal belongings. Participants and or/accompanying persons should make their own arrangements with respect to personal insurance.

### Mobile Phones and Pagers

As a courtesy to speakers and other delegates, we request that all mobile phones and pagers are in silent mode or switched off before entering sessions.

#### Messages

The Conference registration desk staff will take messages for delegates during the Conference. Messages will be posted on the message board, located next to the registration desk. Delegates are requested to check the message board during breaks.



#### Name Badges

Your name badge is your entrance ticket to all Conference sessions and the Exhibition. Please wear your name badge at all times.

#### No Smoking Policy

Delegates should be aware that smoking is banned in public buildings and hotels and restaurants throughout Victoria, including the Conference venue.

#### Tickets

Your tickets for the masterclasses, breakfasts and Conference dinner are included in your name badge holder. If you have misplaced your tickets or have not received tickets for functions you wish to attend, please see the staff at the Registration Desk.

#### WIFI

WIFI access is available free of charge throughout the Exhibition and in the Business Centre. Visit the APCR Business Centre in the Trade Area to use the computers.


### Exhibition Information

The Exhibition is located in Main Foyer of the Melbourne Convention Centre and will be open during the following hours:

Sunday 31 August	1000 - 1900
Monday 1 September	0900 - 1700
Tuesday 2 September	0900 – 1530

Exhibitors	
Abbvie Pty Ltd	28
Amgen	8
AMS Australia	10
Astellas	19 & 20
AstraZeneca	27
Australian Prostate Cancer Research	Business Centre
Bayer	6&7
Coloplast	17
Device Technologies	26
Ferring Pharmaceuticals	25
Imaging Solutions	11
Innologic	16
IPSEN Pty Ltd	4 & 5
Janssen	29
Karl Storz Endoscopy	22
Meditron Pty Limited	9
N. Stenning & Co.	12
Neotract Australia Pty Ltd	18
Olympus Australia	2&3
Prostate Cancer Foundation of Australia	14
Sanofi	1
Scanmedics	23
Société Internationale d'Urologie (SIU)	21
Tolmar Australia	24





### Exhibitor Profiles

#### STAND 28

#### Abbvie Pty Ltd



Contact	Tessa James
Address	32-34 Lord Street Botany
	NSW 2019 Australia
Telephone	+61 2 9035 8600
Facsimile	+61 2 9035 8601
Email	tessa.james@abbvie.com
Website	www.abbvie.com.au

AbbVie is a new & different kind of company that combines focus & passion of a leading biotech with expertise & structure of a long established pharmaceutical leader.

We'd like to tell you more about the creative & innovative ways AbbVie is helping support clinicians & their patients. Visit us at the AbbVie stand and www.abbvie.com

#### STAND 8

Amgen

**AMGEN** 

Oncology

Contact	Anne Sullivan
Address	Level 7, 123 Epping Road
	North Ryde NSW 2113 Australia
Telephone	+61 2 9870 1333
Facsimile	+61 2 9870 1344
Email	ausinfo@amgen.com
Website	www.amgen.com.au

Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. A biotechnology pioneer since 1980, Amgen has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.

#### STAND 10

#### AMS Australia



Contact	Pat Callanan
Address	Unit 31 F, 16 Mars Road Cove West
	NSW 2066 Australia
Telephone	+61 2 9425 6800
Facsimile	+61 2 9427 6296
Email	pat.callanan@ammd.com
Website	www.americanmedicalsystems.com

AMS is the world's leading company focused on developing, manufacturing and marketing medical devices that restore male and female pelvic health. AMS Australia utilises this global strength to provide quality solutions and unmatched resources to Urologists throughout Australia and New Zealand covering prosthetic urology, BPH solutions and female urology. Our training initiatives, in surgery support, staff knowledge and staff dedication sees us providing a true partnership in numerous practices throughout Australia and New Zealand for the long term.

#### STAND 19 & 20

#### Astellas Pharma Australia Pty Ltd



Contact	Michelle Commane	
Address	Suite 4, Level 4, 6 Eden Park Drive,	
	Macquarie Park. NSW 2113 Australia	
Telephone	+ 61 2 9814 1100	
Facsimile	+ 61 2 9814 1120	
Website	www.astellas.com.au	



#### AstraZeneca Australia



Contact	Simone Holst
Address	5 Alma Road North Ryde
	NSW 2113 Australia
Telephone	+61 2 9978 3500
Facsimile	+61 2 9978 3700
Website	www.astrazeneca.com.au

AstraZeneca Australia, based in North Ryde, Sydney, is the largest pharmaceutical company operating in Australia. AstraZeneca employ almost 1,000 people, are one of the country's largest manufacturers of medicines and are a key exporter to 35 international markets. AstraZeneca manufactures 100 separate product lines, namely sterile respiratory and local anaesthetic products. Of the top twenty medicines used in Australia, four are made by AstraZeneca. AstraZeneca produces medicines in six separate therapeutic areas including cancer, cardiovascular, gastrointestinal, infection, neuroscience and respiratory inflammation. AstraZeneca contributes significantly to clinical trials in Australia with approximately 30 concurrent trials in 190 sites across the country.

#### STAND 17

#### Coloplast



Contact	Desi Mavros	
Address	33 Gilby Road Mt Waverley	
	VIC 3149 Australia	
Telephone	0403 551 239	
Facsimile	+61 3 9541 1199	
Email	audema@coloplast.com	
Website	www.coloplast.com.au	

Coloplast Porges is a leading global manufacturer and marketer of innovative medical devices for the management

and treatment of urological conditions to include incontinence, pelvic organ prolapse, Peyronie's Disease and ED. Products include: Titan®/Genesis® penile prostheses, Virtue® male sling, Torosa®/KiWeeTM testicular prostheses, Restorelle® mesh, Aris®/Supris™/Altis™ sling systems, BoNee® bladder injection needles.

#### **Business Centre**

#### Australian Prostate Cancer Research



Contact James Garland Address Locked Bag 10, East Melbourne, 8002, VICTORIA Telephone +61 3 9421 0985 Email info@apcr.org.au Website www.prostatecancerresearch.org.au

Australian Prostate Cancer Research is a national research organisation that partners with leading institutions to develop, fund and deliver national research programs. We are committed and driven to discover new tests, new treatments and to educate the industry on all aspects of diagnosis, treatment and patient care.



#### Device Technologies



Contact	Marta Orczykowska
Address	1 Garigal Road Belrose
	NSW 2085 Australia
Telephone	1800 429 551
Facsimile	1800 999 323
Email	davinci@device.com.au
Website	www.device.com.au

Founded in 1992, Device Technologies is an established distributor of quality and technologically-advanced medical equipment and consumables. The company is Australian-owned and employs more than 500 healthcare specialists and support staff in Australia and New Zealand.

- All products are professionally supported by qualified Product Managers and specialists, trained to work in surgical and operating room environments.
- Clinical Educators provide accredited training, in-servicing and ongoing clinical support.
- Technical Service personnel service and maintain our extensive range of capital equipment.
- Regulatory Affairs ensure all products are correctly listed with the TGA.

Company Mission Statement:

To enable superior health outcomes for patients, by providing access to the best medical systems available worldwide

#### STAND 25

#### Ferring Pharmaceuticals



Ferring Pharmaceuticals is a Swiss-based research-oriented pharmaceutical company that specialises in products in the field of Urology/Oncology, Gastroenterology, Endocrinology and Reproductive Health. At this meeting, Ferring Pharmaceuticals is featuring FIRMAGON® (degarelix), a GnRH receptor antagonist. Visit us at the Ferring stand to learn about FIRMAGON® and its reconstitution and administration process.

#### STAND 11

#### Imaging Solutions



FERRING

PHARMACEUTICALS

Contact	Renee Campbell
Address	PO BOX 1768 Sunnybank Hills
	QLD 4109
Telephone	+61 7 3209 9712
Facsimile	+61 7 3209 9812
Email	r.campbell@imagingsol.com.au
Website	www.imagingsol.com.au

Imaging Solutions is a healthcare imaging equipment products and consumables supplier. Our critical point of difference is our "single source supplier" philosophy which allows us to offer unmatched convenience and value for money to all our customers. Imaging Solutions offers an extensive range of world-market-leading, first quality, high performance products which assist our customers in delivering outstanding radiographic diagnostic quality first time, every time.



#### Innologic

### innologic 📰

Contact	Dale Johnston
Address	6 Gould Street, Herdsman Business
	Park, Osborne Park WA 6017
Telephone	1300 729 069
Facsimile	+61 2 8583 3333
Email	info@innologic.com.au
Website	www.innologic.com.au

Innologic's focus is innovation in healthcare combined with exceptional customer service.

Each device in our range was selected for its quality, reliability, & ability to support the needs of busy clinics. We are focused on being the preferred supplier of equipment, technical service & associated clinical support for our customers.

#### **STAND 4 & 5**

Contact

#### **IPSEN Pty Ltd**



Contact	
Address	Level 2, Building 4, Brandon Office
	Park, 540 Springvale Road
	Glen Waverley VIC 3150 Australia
Telephone	+61 3 8544 8100
Facsimile	+61 3 9562 5152
Email	info@ipsen.com.au
Website	www.ipsen.com.au

Kolly Gillin

Ipsen provides specialty medicines and quality services to Healthcare Professional and their patients suffering from debilitating diseases.

At Ipsen, our passion is improving the lives of patients. We do this by working together to build partnerships based on trust and mutual respect with Healthcare Professionals. We deliver tailored solutions through our agility and innovation and we strive to be even better tomorrow than we are today.

Ipsen Pty Ltd is the Australian affiliate of a global R & D focused pharmaceutical company.

#### STAND 29

#### Janssen Contact

Jacqui Wade



Contact	buoqui muuo	, ,
Address	66 Waterloo Road Ma	acquarie Park
	NSW 2113 Australia	
Telephone	+61 2 9815 3380	
Facsimile	+61 2 9475 0316	
Email	oncology@its.jnj.con	n
Website	www.janssen.com.au	I

Janssen Pharmaceutical Companies of Johnson & Johnson are dedicated to addressing and solving the most important unmet medical needs of our time, including oncology (e.g. multiple myeloma, Prostate, Ovarian and Breast cancer), immunology (e.g. psoriasis), neuroscience (e.g. schizophrenia, dementia and pain), infectious disease (e.g. HIV/AIDS, Hepatitis C and tuberculosis), and cardiovascular and metabolic diseases (e.g. diabetes).

#### STAND 22

#### Karl Storz Endoscopy



Contact	Amanda Silverstone
Address	Annex Building, 15 Orion Road
	Lane Cove West NSW 2066 Australia
Telephone	+61 2 9490 6700
Facsimile	+61 2 9420 0695
Email	karlstorz@karlstorz.com.au
Website	www.karlstorz.com

KARL STORZ has established itself worldwide as an international and highly regarded company in the production and sale of endoscopic devices, documentation and cameras. The majority of manufacturing is carried out in Tuttlingen, Germany where the art of instrument making is alive and well.

We will be showcasing the newest products to the market, including CMOS Video Cystoscope, 7Fr semi rigid ureteroscope, Green Light Laser Telescope and High Flow Sheath and UROMAT EASI, the newest Fluid Management System on the market.

#### Meditron Pty Limited



Contact	Michael Fehrmann
Address	PO Box 4230 Ringwood
	VIC 3134 Australia
Telephone	+61 3 9879 6200
Facsimile	+61 39879 6244
Email	info@meditron.com.au
Website	www.meditron.com.au

Meditron supply the complete range of Dornier MedTech products. These include Lithotripters, Urotables, Holmium Stone Laser and the UroBeam laser for BPH.

Meditron also offers technology for MRI-Fusion and intelligent Perineal Prostate Biopsies.

Furthermore, Meditron distribute CIVCO transducer covers and needle guides for TRUS-procedures.

#### STAND 12

Contact

#### N. Stenning & Co.



oomaar	Bereitt eitilt
Address	174 Parramatta Road Camperdown
	NSW 2050 Australia
Telephone	+61 2 8594 9100
Facsimile	+61 2 8594 9188
Email	nstenning@nstenning.com.au
Website	www.nstenning.com.au

N. Stenning & Co. has been proudly selling innovative equipment for over 60 years in the medical devices industry. Featured will be our Hemo-lok ligating clip system, Storz Medical ESWT and ESWL, and other medical devices specifically for prostate surgery.

#### STAND 18

#### Neotract Australia Pty Ltd



Contact	Tracee Stannard
Address	Unit 13 76 Reserve Road Artarmon
	NSW 2064 Australia
Telephone	+61 2 9436 0487
Facsimile	+61 2 9475 4558
Email	tstannard@neotract.com
Website	www.neotract.com

NeoTract, Inc. is dedicated to developing innovative, minimally invasive and clinically effective devices that address unmet needs in urology. Our initial focus is on improving the standard of care for patients with BPH using the UroLift® System, a minimally invasive permanent device designed to treat LUTS. Learn more at www.UroLift.com.

#### **STAND 2 & 3**

#### Olympus Australia



Contact	Jada Tomas
Address	3 Acacia Place, Notting Hill VIC 3168
Telephone	+61 3 9271 5513
Facsimile	+61 3 9562 6416
Email	jada.tomas@olympus.com.au
Website	www.olympusaustralia.com.au

Olympus is an innovative technology and service provider, excelling in the field of Urology. With the complete product portfolio in Urology offering unique video scopes and bipolar PlasmaButton Vaporisation in addition to our range of Endourology consumable products, we are the company to partner with for your daily diagnostic and therapeutic requirements.



#### Prostate Cancer Foundation of Australia



Contact	Marieke Koets
Address	Level 3, 39 Chandos Street
	St Leonards NSW 2065
Telephone	+61 2 9438 7095
Facsimile	+61 2 9438 7099
Email	Marieke.Koets@pcfa.org.au
Website	www.prostate.org.au

Prostate Cancer Foundation of Australia (PCFA) is a broad-based community organisation and the peak national body for prostate cancer in Australia. We are dedicated to reducing the impact of prostate cancer on Australian men, their partners, families and the wider community.

We do this by:

- Promoting and funding world leading, innovative research into prostate cancer
- Implementing awareness campaigns and education programs for the Australian Community, health professionals and Government
- Supporting men and their families affected by prostate cancer through evidence-based information and resources, support groups and Prostate Cancer Specialist Nurses

PCFA receives Government funding for specific projects and relies on the generosity of individuals, the community and partnerships, such as those with the Movember Foundation and Commonwealth Bank, to carry out our essential work.

#### STAND 1

#### Sanofi



Contact	
Address	Talavera Corporate Centre 12 – 24
	Talavera Road Macquarie Park
	NSW 2133 Australia
Telephone	+61 2 8666 2000
Facsimile	+61 2 8666 3000
Website	www.sanofi.com.au

The ambition of Sanofi is to become a diversified global healthcare leader, focused on patients' needs, the largest pharmaceutical company in Europe and in emerging markets, Sanofi is the fourth largest worldwide. The Group's vaccine division, Sanofi Pasteur, is the world leader for human vaccine production and commercialisation.

#### **STAND 23**

#### **Scanmedics**



Contact	Paul Blewitt	PRODUCTS YOU TRUST FROM PEOPLE YO
Address	Unit 6 15-17 Gibb	es Street
	Chatswood NSW	2067 Australia
Telephone	+61 2 9882 2088	
Facsimile	+61 2 9882 3549	
Email	scanmedics@sca	anmedics.com
Website	www.scanmedics	.com

Scanmedics has been the provider of BK Medical ultrasound solutions for over 18 years in Australia and New Zealand. Founded in 1996 by MaryAnne Taylor and David Gibson, the Scanmedics team has attained a reputation for working with clinicians to support patient centred care while improving their clinical outcomes. BK Medical's superior image quality with Quantum+ technology makes a diagnostic difference to prostate imaging.

#### Société Internationale d'Urologie (SIU)



Address	1155 University Street, Suite 1012
	Montreal, QC H3B 3A7 Canada
Telephone	+1 514 875 5665
Facsimile	+1 514 875 0205
Email	central.office@siu-urology.org
Website	www.siu-urology.org

The Société Internationale d'Urologie (SIU) prides itself on fulfilling the educational needs of its members, and on mobilizing technology to reach the greatest numbers of urologists worldwide. In October 2014, the SIU launched its virtual platform enabling the SIU Congress to go hybrid. Visit Booth # 21 to learn more about our 35th congress in Melbourne, Australia, Oct. 15 – 18, 2015. Visit us at: www.siu-urology.org for more information on the different facets of the SIU.

#### STAND 24

#### Tolmar Australia



Contact	Michael Sapurmas
Address	Building 2 Level 2 Suite 4,
	20 Bridge St Pymble NSW 2073
Telephone	+61 2 9440 6700
Facsimile	+61 2 9440 6750
Email	Carolyn.tabrett@tolmar.com.au
Website	www.tolmar.com.au

New uro-oncology player Tolmar Australia is well resourced and motivated to support real improvements in the quality of life for men with prostate cancer. The company sponsors an innovative in-home injection service, Eligard® NurseCARE (independently run by AESIR Health), that aims to ease the treatment experience. TOLMAR is actively looking to fund researchers to encourage further advancements. With a collaborative mindset, Tolmar Australia is also a proud sponsor of the Prostate Cancer Foundation of Australia.

# Join the conversation on Twitter!

Follow @AustProstate and #apcc14 for latest updates



# TOGETHER IN DISCOVERY AND CARE COME TOGETHER

www.prostatecancerconference.org.au

PRESENTED BY





Follow us on twitter #apcc14 @AustProstate